Previous close | 0.4200 |
Open | 0.4200 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 165.00 |
Expiry date | 2025-01-17 |
Day's range | 0.4200 - 0.4200 |
Contract range | N/A |
Volume | |
Open interest | 15 |
Pharmaceutical majors Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) have experienced a significant increase in their market value on Thursday, driven by the potential of their weight-loss drugs, GLP-1s, to address the global obesity epidemic. This optimism has propelled sales forecasts into the hundreds of billions. However, this same optimism has negatively impacted companies that have traditionally profited from treating obesity-related complications.
Leading pharmaceutical companies, Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY), are anticipated to see significant revenue growth from their newly developed obesity drugs, according to financial analysts' predictions. These medications, known as GLP-1 receptor agonists, are considered the safest and most effective weight-loss drugs currently available. They offer potential body weight reductions of up to 20% and could also diminish patients' risk of heart attack or stroke.
You don't have to invest in artificial intelligence or the latest tech company to earn great returns on your investments. The healthcare industry is full of promising investment opportunities of its own. DexCom (NASDAQ: DXCM), Eli Lilly (NYSE: LLY), and West Pharmaceutical Services (NYSE: WST) are three stocks that have each turned $100,000 investments into $1 million over the past 10 years.